타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) 10 trials |
|---|---|
Overview Program | Adstiladrin (nadofaragene firadenovec) |
Overview Company | Ferring Pharmaceuticals |
Overview Modality | CGT |
Overview Target | IFNα2b (adenoviral) |
Overview Indication | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Local bladder gene delivery avoiding systemic AAV exposure |
Positioning Known limitation | downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo |
Technology Vector | rAd-IFNα/Syn3 |
MoA Mechanism | Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC. |
MoA Biomarker | Complete response at 3/6/12 months (cystoscopy, cytology, biopsy). |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Toxicology CRS | N/A |
Clinical Safety signal | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Clinical Program phase | APPROVED |
Clinical Trial activity | 6 recruiting · 3 completed |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) 10 trials |
|---|---|
Overview Program | Adstiladrin (nadofaragene firadenovec) |
Overview Company | Ferring Pharmaceuticals |
Overview Modality | CGT |
Overview Target | IFNα2b (adenoviral) |
Overview Indication | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Local bladder gene delivery avoiding systemic AAV exposure |
Positioning Known limitation | downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo |
Technology Vector | rAd-IFNα/Syn3 |
MoA Mechanism | Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC. |
MoA Biomarker | Complete response at 3/6/12 months (cystoscopy, cytology, biopsy). |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Toxicology CRS | N/A |
Clinical Safety signal | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Clinical Program phase | APPROVED |
Clinical Trial activity | 6 recruiting · 3 completed |
추천 비교
추천 비교